PubRank

I J Jacobs

Author PubWeight™ 55.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000 2.04
2 p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998 1.79
3 Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993 1.71
4 PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001 1.63
5 Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 2007 1.61
6 Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993 1.60
7 Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001 1.55
8 Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995 1.27
9 Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002 1.21
10 Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet 2001 1.21
11 Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG 2007 1.15
12 Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br J Cancer 1999 1.13
13 The role of CA 125 in screening for ovarian cancer. Int J Biol Markers 1999 1.12
14 Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer 2009 1.08
15 Ascites and a raised serum Ca 125--confusing combination. J R Soc Med 2001 1.08
16 A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 2002 1.08
17 Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 2000 1.03
18 Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 2000 1.02
19 The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol 2005 1.02
20 Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif 2009 1.02
21 Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. Radiology 1999 1.00
22 Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol 2001 0.99
23 Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000 0.97
24 Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int J Gynecol Cancer 2007 0.97
25 Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. BJOG 2006 0.96
26 Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000 0.95
27 Screening for ovarian cancer. Ann Acad Med Singapore 1998 0.93
28 Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry. J Clin Pathol 2003 0.90
29 Can MRI rule out bladder and rectal invasion in cervical cancer to help select patients for limited EUA? Gynecol Oncol 2005 0.90
30 Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol 2001 0.89
31 Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer 2001 0.88
32 Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol 1999 0.85
33 Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999 0.84
34 Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. Br J Cancer 2009 0.84
35 Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest 2001 0.83
36 Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer 1999 0.83
37 Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer. Gynecol Oncol 2006 0.81
38 Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis. J Natl Cancer Inst 1998 0.81
39 Early diagnosis of ovarian cancer. Br J Hosp Med 1990 0.80
40 Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems. Histopathology 2007 0.79
41 Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol Pathol 2002 0.79
42 Is there a place for screening in ovarian cancer? Eur J Obstet Gynecol Reprod Biol 1999 0.78
43 Increased mortality in postmenopausal women with serum CA125 elevation. Gynecol Oncol 1999 0.78
44 High frequency of loss of heterozygosity in vulval intraepithelial neoplasia (VIN) is associated with invasive vulval squamous cell carcinoma (VSCC). Int J Cancer 2001 0.78
45 Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG 2000 0.78
46 p53 codon 72 polymorphism in vulval cancer and vulval intraepithelial neoplasia. Br J Cancer 2000 0.77
47 Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 1995 0.76
48 No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis. Gynecol Oncol 1998 0.76
49 Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 2000 0.76
50 Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. Int J Gynecol Cancer 2004 0.76
51 Familial ovarian screening--effective or ineffective? Br J Cancer 2006 0.76
52 A review of post-trachelectomy isthmic and vaginal smear cytology. Cytopathology 2004 0.76
53 Clinical value of immunohistochemically detected lymphovascular invasion in endometrioid endometrial cancer. Gynecol Oncol 2004 0.76
54 Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma. Br J Cancer 2003 0.75
55 Comment on Elit et al.: prophylactic oophorectomy in Ontario. Fam Cancer 2001 0.75
56 A biochemical test for the direct assessment of endometrial function: measurement of the major secretory endometrial protein PP14 in serum during menstruation in relation to ovulation and luteal function. Hum Reprod 1990 0.75
57 Tumor markers in screening for ovarian cancer. Methods Mol Med 2001 0.75
58 OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin Chem 1999 0.75
59 Familial ovarian cancer. Methods Mol Med 2001 0.75
60 Laparoscopic extraperitoneal paraaortic lymphadenectomy: a study of its applications in gynecological malignancies. Gynecol Oncol 2004 0.75
61 Assessment of the depth of myometrial invasion in stage I endometrioid endometrial cancer using pancytokeratin immunohistochemistry. Int J Gynecol Cancer 2004 0.75